CHICAGO, April 23, 2013 /PRNewswire/ -- Since January, Scotland has announced significant progress on several major life science discoveries slated to treat life-threatening diseases such as cancer, HIV and leukemia.
Scotland offers the UK's fastest R&D approval times and already ranks as the leading UK region for R&D investment, according to data from Ernst & Young. With industry challenges on the rise, Scotland continues to rely on its renowned R&D capabilities to generate sector growth.
To showcase their latest discoveries, 20 of Scotland's leading life science companies and research organizations are accompanying Scottish Development International, the country's economic development agency, at the 2013 BIO International Convention, April 22-25.
"Scotland continues to attract major investments from some of the world's leading life sciences companies including GlaxoSmithKline and LifeScan, further strengthening Scotland's position as a key cluster for life sciences innovation," notes Danny Cusick , President, Americas, of Scottish Development International.
Today, Scotland's BioOutsource, a global leader in the biological analysis of biosimilar molecules for the biopharmaceutical industry, announced its first facility opening in the U.S. To be based in Cambridge, Massachusetts the company believes the expansion will link Scotland's strong life science services to Boston's growing venture capital landscape.
In February, the University of Dundee and incubator campus, BioCity Scotland, won a project worth $128 million to discover new drug treatments—marking the biggest investment of its kind in
|SOURCE Scottish Development International|
Copyright©2012 PR Newswire.
All rights reserved